Sandeep Sisodiya

Mr. Sandeep Sisodiya


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
BBBanashree Bondhopadhyay
Banashree Bondhopadhyay
SSSandeep Sisodiya
Sandeep Sisodiya
Faisal A AlzahraniFaisal A Alzahrani
Faisal A Alzahrani
MBMuhammed Bakhrebah
Muhammed Bakhrebah
Atul ChikaraAtul Chikara
Atul Chikara
Showket HussainShowket Hussain
Showket Hussain
Despite the recent advancements in therapeutics and personalized medicine, breast cancer remains one of the most lethal cancers among women. The prognostic and diagnostic aids mainly include assessment of tumor tissues with conventional methods towards better therapeutic strategies. However, current era of gene-based research may influence the treatment outcome particularly as an adjunct to diagnostics by exploring the role of non-invasive liquid biopsies or circulating markers. The characterization of tumor milieu for physiological fluids has been central to identifying the role of exosomes or small extracellular vesicles (sEVs). These exosomes provide necessary communication between tumor cells in the tumor microenvironment (TME). The manipulation of exosomes in TME may provide promising diagnostic/therapeutic strategies, particularly in triple-negative breast cancer patients. This review has described and highlighted the role of exosomes in breast carcinogenesis and how they could be used or targeted by recent immunotherapeutics to achieve promising intervention strategies.

14 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AKAsiya Khan
Asiya Khan
SSSandeep Sisodiya
Sandeep Sisodiya
MAMehreen Aftab
Mehreen Aftab
PTPRANAY TANWAR
PRANAY TANWAR
Showket HussainShowket Hussain
Showket Hussain
VGVivek Gupta
Vivek Gupta
Background: As per recent scenarios, drug resistance is a significant challenge in treating breast cancer for several reasons, such as genetic mutations, altered signaling pathways, and tumor microenvironment. Endocrine resistance is one of the biggest significant barriers to treatment, particularly in hormone receptor-positive (HR+) breast cancers, which depends on estrogen or progesterone signaling for growth. While therapies such as tamoxifen, aromatase inhibitors, and selective estrogen receptor degraders (SERDs) have effectively targeted these pathways, many patients develop resistance, rendering them less effective over time, which is driving a need for innovative therapeutics to treat breast cancer and overcome drug resistance and better treatment outcomes. Recent studies suggest that combining the different therapies, including immunotherapy, targeted therapy, chemotherapy, etc., with endocrine therapy, may bypass the endocrine resistance. Methodology: We conducted a comprehensive systematic review and meta-analysis examining the molecular mechanisms of endocrine resistance and evaluating randomized clinical trial outcomes, overall survival and progression-free survival in endocrine-resistant breast cancer patients treated with endocrine therapy, targeted therapy, immunotherapy, or chemotherapy. Results: We have analyzed 35 randomized clinical trial studies for different therapies along with combination therapy, and our results demonstrated that supplementary or additional therapies in endocrine resistance breast cancer patients have better progression-free and overall survival. Conclusions: The current study has demonstrated that combination therapies may have good survival results and patient outcomes in endocrine resistance. Also, This review sheds light on current challenges in drug resistance and the future direction of cancer treatment through a comprehensive analysis of these emerging treatment approaches to improve patient outcomes.

14 August 2024 in International Journal of Surgery
Verified
Journal Article
Open access
SASupriya Mtech Awasthi
Supriya Mtech Awasthi
RKRahul Kumar
Rahul Kumar
DPDibyabhaba Pradhan
Dibyabhaba Pradhan
NRNeetu Rawal
Neetu Rawal
Harsh GoelHarsh Goel
Harsh Goel
PTPRANAY TANWAR
PRANAY TANWAR
Background: Gallbladder cancer (GBC) is a common gastrointestinal malignancy noted for its aggressive characteristics and poor prognosis, which is mostly caused by delayed detection. However, the scarcity of information regarding somatic mutations in Indian patients with GBC has hampered the development of efficient therapeutic options. In the present study, the authors attempted to bridge this gap by revealing the mutational profile of GBC. Materials and methods: To evaluate the somatic mutation profile, whole exome sequencing (WES) was performed on 66 tumor and matched blood samples from individuals with GBC. Somatic variant calling was performed using GATK pipeline. Variants were annotated at pathogenic and oncogenic levels, using ANNOVAR, VEP tools and the OncoKB database. Mutational signature analysis, oncogenic pathway analysis and cancer driver genes identification were performed at the functional level by using the maftools package. Results: Our findings focused on the eight most altered genes with pathogenic and oncogenic mutations: TP53, SMAD4, ERBB3, KRAS, ARID1A, PIK3CA, RB1, and AXIN1. Genes with pathogenic single nucleotide variations (SNVs) were enriched in oncogenic signaling pathways, particularly RTK-RAS, WNT, and TP53 pathways. Furthermore, our research related certain mutational signatures, such as cosmic 1, cosmic 6, and cosmic 18, 29, to known characteristics including patient age and tobacco smoking, providing important insights into disease etiology. Conclusions: Given the scarcity of exome-based sequencing studies focusing on the Indian population, this study represents a significant step forward in providing a framework for additional in-depth mutational analysis. Genes with substantial oncogenic and pathogenic mutations are promising candidates for developing targeted mutation panels, particularly for GBC detection.

26 March 2026 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
SSSandeep Sisodiya
Sandeep Sisodiya
PSPayal Singh
Payal Singh
TJTannu Joshi
Tannu Joshi
AKAsiya Khan
Asiya Khan
NMNeetu Mishra
Neetu Mishra
Showket HussainShowket Hussain
Showket Hussain

26 September 2025 in 3 Biotech
Verified
Journal Article
Closed access
PDF file
BBBanashree Bondhopadhyay
Banashree Bondhopadhyay
NANavya Aggarwal
Navya Aggarwal
MCMukesh Chourasia
Mukesh Chourasia
SSSandeep Sisodiya
Sandeep Sisodiya
Showket HussainShowket Hussain
Showket Hussain

6 July 2022
Verified
Book Chapter
Closed access
PDF file
Showket HussainShowket Hussain
Showket Hussain
SSSandeep Sisodiya
Sandeep Sisodiya
VKVishakha Kasherwal
Vishakha Kasherwal
STSonam Tulsyan
Sonam Tulsyan
Asiya KhanAsiya Khan
Asiya Khan
Traditional drug discovery is expensive and time-consuming, which raises the question of a drug development process with shortened time and cost. Computer-aided drug designing (CADD) revolutionized the pharmaceutical industry in guiding towards the discovery of small molecules having therapeutic relevance. In recent decades, rapid evolution of rational drug discovery tools accelerates the process of CADD. CADD is categorized into structure-based drug design (SBDD) and ligand-based drug design (LBDD). SBDD requires the 3D structure of the target followed by identification of the binding site, screening of compounds and molecular docking, whereas LBDD does not require prior information about the 3D structure of the target and relies on the methods of the quantitative structure activity relationship (QSAR) and pharmacophore modelling. Toxicity prediction and optimization of lead compounds were done for their advancement against specific disease and to minimize the side effects by assessing their physiological and pharmacokinetics properties. In this chapter, the CADD steps will be discussed with emphasis on the methodologies for therapeutics development against women-associated cancer.